#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ependymoma Head and neck cancer Hypersomnia Facioscapulohumeral muscular dystrophy Hypochondroplasia Breast angiosarcoma Epstein-Barr virus infection Cholangitis sclerosing Proteus syndrome Glioblastoma Neuropathy peripheral Primary mediastinal large B-cell lymphoma Crigler-Najjar syndrome Extra-osseous Ewing's sarcoma metastatic Ureteric cancer More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Trials in Disease Propionic acidaemia – Treatment Erdheim-Chester disease – Trials in Disease Leiomyosarcoma recurrent – Treatment Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment Inclusion body myositis – Diagnostics CADASIL – Diagnostics Netherton’s syndrome – Diagnostics Myelodysplastic syndrome – Basic Information Lennox-Gastaut syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ripretinib Ro7589655 Purified Egg Phospholipids Afamelanotide Bms-986449-03 Amniotic Membrane, Human Atomoxetine Teriflunomide Dyp688 Oxazepam Oxygen Ph.eur. Nitrofurantoin Briquilimab Nalbuphine Hydrochloride Diclofenac Remifentanil Hydrochloride Tominersen Soya-Bean Oil Refined Mitotane Colistimethate Sodium More therapies…

    Learn about Your Condition

    Coronary artery disease Milk allergy Glomerulonephritis chronic Drug use disorder Alopecia areata Biliary tract disorder Ocular lymphoma Triple negative breast cancer Pertussis Metastatic neoplasm Meningococcal infection Peripheral artery stenosis Dystonic tremor Chronic hepatic failure Schizoaffective disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. CHU d’Estaing

CHU d’Estaing

1 place Lucie et Raymond Aubrax, Clermont Ferrand, 63100, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TAGRAXOFUSP
    • Venetoclax
    France

  • Study on EXL01 for Preventing Crohn’s Disease Recurrence After Surgery in Patients

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Exl01
    France

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Primary myelofibrosis
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pioglitazone
    • Avelumab
    France

  • Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Tumour of ampulla of Vater
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Fluorouracil
    France

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Dactinomycin
    • Ifosfamide
    • Regorafenib
    Austria Belgium Czechia Denmark Finland France +10

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • Dinutuximab Beta
    • Melphalan
    • Irinotecan Hydrochloride Trihydrate
    Austria Belgium Czechia Denmark Finland France +11

  • Study of Oxaliplatin, Nivolumab, and Trifluridine/Tipiracil for Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Gastric cancer
    • Gastric cancer recurrent
    Investigated Drugs:
    • Levoleucovorin
    • Tipiracil Hydrochloride
    • Tipiracil
    France

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Irinotecan Hydrochloride Trihydrate
    • Cisplatin
    • Etoposide
    France

  • Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Levoleucovorin
    • Capecitabine
    • Fluorouracil
    Belgium France
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!